Convalescent Plasma
Cross-source consensus on Convalescent Plasma from 1 sources and 4 claims.
1 sources · 4 claims
Uses
How it works
Background
Evidence quality
Highlighted claims
- Convalescent plasma from recovered COVID-19 patients provides passive antibody-mediated immunity and requires blood type matching for safe administration. — COVID-19 ICU Treatment Protocols: Medications, Prone Positioning, and Emerging Evidence
- Convalescent plasma was experimental in COVID-19 with no randomized evidence, though it had demonstrated efficacy in approximately a dozen other viral diseases. — COVID-19 ICU Treatment Protocols: Medications, Prone Positioning, and Emerging Evidence
- Emergency use of convalescent plasma required submitting a patient clinical summary to the CDC/FDA, with authorization possible within two hours. — COVID-19 ICU Treatment Protocols: Medications, Prone Positioning, and Emerging Evidence
- Convalescent plasma availability improved over the course of the pandemic from approximately one week wait to one to two days in Southern California. — COVID-19 ICU Treatment Protocols: Medications, Prone Positioning, and Emerging Evidence